The relationship between HLA-A, B, DQ, and DR antigens and asbestos-induced lung disease.
To evaluate the relationship between human leukocyte antigen (HLA) and both asbestos-induced pulmonary fibrosis and pleural fibrosis, we obtained HLA-A, B, C, DQ, and DR phenotypes in 42 long-term asbestos-exposed workers. Among these exposed workers, 15 had asbestosis (ILO > or = 1/0) on the chest radiograph and 18 had asbestos-induced pleural fibrosis. We found that there was an increased percentage of HLA-A29, HLA-B44, and HLA-Bw4 in the subjects with asbestosis. In addition, we observed a marginally positive relationship between HLA-A29 and the severity of pulmonary fibrosis. Similarly, there was a higher prevalence of HLA-DRw53 and DQ2 in the subjects with asbestos-induced pleural fibrosis. The presence of HLA-DQ2 was significantly related to the extent and type of asbestos-induced pleural fibrosis while HLA-DRw53 was not consistently related to the type or extent of pleural disease. Importantly, we observed that HLA-A29, HLA-B44, HLA-Bw4, HLA-DRw53, and HLA-DQ2 do not have a significantly shorter duration or latency of asbestos exposure. Moreover, none of the HLA haplotypes (A29, B44, Bw4, DRw53, and DQ2) that we found to be associated with radiographic manifestations of asbestos-induced lung disease were associated with the physiologic abnormalities that have been traditionally associated with asbestos-induced lung disease. The only exception was an isolated decrease in the residual volume associated with the presence of HLA-A29. These results suggest that the HLA-A29 phenotype may be associated with the development of asbestosis and the HLA-DQ2 phenotype may be associated with the development of asbestos-induced pleural fibrosis. However, these associations are not particularly strong, physiologic correlation is lacking, and previous studies do not support our findings.
Shih
J F
JF
Department of Internal Medicine, Department of Veterans Affairs, Iowa City.
Hunninghake
G W
GW
Goeken
N E
NE
Galvin
J R
JR
Merchant
J A
JA
Schwartz
D A
DA
D001195:Asbestosis / Q000276:immunology*; D005355:Fibrosis; D015234:HLA-A Antigens / Q000032:analysis*; D015235:HLA-B Antigens / Q000032:analysis*; D059948:HLA-B44 Antigen; D006683:HLA-DQ Antigens / Q000032:analysis*; D006684:HLA-DR Antigens / Q000032:analysis*; D059845:HLA-DRB4 Chains; D006801:Humans; D008297:Male; D008875:Middle Aged; D010995:Pleural Diseases / Q000276:immunology*; D011658:Pulmonary Fibrosis / Q000276:immunology*; D012129:Respiratory Function Tests; D012907:Smoking; D013997:Time Factors
D015234:HLA-A Antigens; C035524:HLA-A29 antigen; D015235:HLA-B Antigens; D059948:HLA-B44 Antigen; C042388:HLA-Bw4 antigen; D006683:HLA-DQ Antigens; C053186:HLA-DQ2 antigen; D006684:HLA-DR Antigens; C050610:HLA-DR53; D059845:HLA-DRB4 Chains